These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 22039668

  • 1. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
    Kupś-Rzepecka J, Woźniakowska-Gesicka T, Gołabek V.
    Przegl Lek; 2011; 68(6):311-5. PubMed ID: 22039668
    [Abstract] [Full Text] [Related]

  • 2. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
    Serranti D, Indolfi G, Nebbia G, Cananzi M, D'Antiga L, Ricci S, Stagi S, Azzari C, Resti M, Italian Study Group for Treatment of Chronic Hepatitis C in Children.
    Pediatr Infect Dis J; 2018 Apr; 37(4):287-291. PubMed ID: 28953189
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
    Bini EJ, Mehandru S.
    Arch Intern Med; 2004 Nov 22; 164(21):2371-6. PubMed ID: 15557418
    [Abstract] [Full Text] [Related]

  • 5. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E, Musialik J, Suchecka W, Petelenz M, Hartman M, Lichtański P, Błońska-Fajfrowska B.
    Wiad Lek; 2010 Nov 22; 63(4):289-99. PubMed ID: 21608370
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.
    Am J Kidney Dis; 2013 Oct 22; 62(4):789-95. PubMed ID: 23746377
    [Abstract] [Full Text] [Related]

  • 7. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    Hwang Y, Kim W, Kwon SY, Yu HM, Kim JH, Choe WH.
    Korean J Intern Med; 2015 Nov 22; 30(6):792-800. PubMed ID: 26552454
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study [KULDS] Group.
    J Gastroenterol Hepatol; 2012 Jul 22; 27(7):1233-40. PubMed ID: 22098185
    [Abstract] [Full Text] [Related]

  • 9. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N, Besheer T, Gad Y, Elbendary A, Mokbel T, Abdel-Aziz A.
    J Ocul Pharmacol Ther; 2013 Apr 22; 29(3):345-8. PubMed ID: 23113644
    [Abstract] [Full Text] [Related]

  • 10. Treatment of chronic hepatitis C in children with pegylated interferon α2a and ribavirin--a multi-center study.
    Słuzewski W, Kowala-Piaskowska A, Wysocki J, Figlerowicz M, Gorczyca A, Halota W, Jóźwiak H, Mizerski J, Mozer-Lisewska I, Pawłowska M, Rokitka M, Strawińska E, Szamotulska K.
    Acta Pol Pharm; 2012 Apr 22; 69(2):319-26. PubMed ID: 22568047
    [Abstract] [Full Text] [Related]

  • 11. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
    Gluhovschi C, Gadalean F, Kaycsa A, Curescu M, Sporea I, Gluhovschi G, Petrica L, Velciov S, Bozdog G, Bob F, Vernic C, Cioca D.
    Immunopharmacol Immunotoxicol; 2011 Dec 22; 33(4):744-50. PubMed ID: 21320001
    [Abstract] [Full Text] [Related]

  • 12. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
    Slim J, Afridi MS.
    Infect Dis Clin North Am; 2012 Dec 22; 26(4):917-29. PubMed ID: 23083824
    [Abstract] [Full Text] [Related]

  • 13. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
    Kee KM, Lee CM, Wang JH, Tung HD, Changchien CS, Lu SN, Wang PW.
    J Gastroenterol Hepatol; 2006 Jan 22; 21(1 Pt 2):319-26. PubMed ID: 16460494
    [Abstract] [Full Text] [Related]

  • 14. Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.
    Nadeem A, Aslam M, Khan DA, Hussain T, Khan SA.
    J Coll Physicians Surg Pak; 2009 Feb 22; 19(2):86-9. PubMed ID: 19208310
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
    Chang YK, Tseng YT, Chen KH, Chen KT.
    BMC Endocr Disord; 2019 Apr 05; 19(1):36. PubMed ID: 30953492
    [Abstract] [Full Text] [Related]

  • 16. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
    Kowala-Piaskowska A, Mozer-Lisewska I, Figlerowicz M, Słuzewski W.
    Pharmacoepidemiol Drug Saf; 2007 Oct 05; 16(10):1095-103. PubMed ID: 17724740
    [Abstract] [Full Text] [Related]

  • 17. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin.
    Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK.
    J Hepatol; 2010 Apr 05; 52(4):501-7. PubMed ID: 20189674
    [Abstract] [Full Text] [Related]

  • 18. Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010.
    Barut S, Gunal O, Erkorkmaz U, Yildiz F.
    Braz J Infect Dis; 2012 Apr 05; 16(5):448-51. PubMed ID: 22964290
    [Abstract] [Full Text] [Related]

  • 19. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B, Kovács B, Battyáni Z.
    Orv Hetil; 2011 Dec 11; 152(50):1997-2009. PubMed ID: 22112373
    [Abstract] [Full Text] [Related]

  • 20. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS, Chu PL, Liu CH, Chung GB, Wu KD.
    J Clin Gastroenterol; 2008 Jan 11; 42(1):112-3. PubMed ID: 18097301
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.